Your browser doesn't support javascript.
loading
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Buisseret, Laurence; Loirat, Delphine; Aftimos, Philippe; Maurer, Christian; Punie, Kevin; Debien, Véronique; Kristanto, Paulus; Eiger, Daniel; Goncalves, Anthony; Ghiringhelli, François; Taylor, Donatienne; Clatot, Florent; Van den Mooter, Tom; Ferrero, Jean-Marc; Bonnefoi, Hervé; Canon, Jean-Luc; Duhoux, Francois P; Mansi, Laura; Poncin, Renaud; Barthélémy, Philippe; Isambert, Nicolas; Denis, Zoë; Catteau, Xavier; Salgado, Roberto; Agostinetto, Elisa; de Azambuja, Evandro; Rothé, Françoise; Craciun, Ligia; Venet, David; Romano, Emanuela; Stagg, John; Paesmans, Marianne; Larsimont, Denis; Sotiriou, Christos; Ignatiadis, Michail; Piccart-Gebhart, Martine.
Affiliation
  • Buisseret L; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium. laurence.buisseret@bordet.be.
  • Loirat D; Medical Oncology Department, Institut Curie, 75005, Paris, France.
  • Aftimos P; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Maurer C; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, 52074, Cologne, Germany.
  • Punie K; Department of General Medical Oncology and Multidisciplinary Breast Unit, Leuven Cancer Institute, University Hospitals Leuven, 3000, Leuven, Belgium.
  • Debien V; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Kristanto P; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Eiger D; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Goncalves A; Medical Oncology Department, Institut Paoli-Calmettes, 13274, Marseille, France.
  • Ghiringhelli F; Medical Oncology Department, Centre Georges-François Leclerc, 21000, Dijon, France.
  • Taylor D; Department of Oncology, CHU-UCL-Namur - Site Sainte-Elisabeth, 5000, Namur, Belgium.
  • Clatot F; Medical Oncology Department, Centre Henri Becquerel, 76038, Rouen, France.
  • Van den Mooter T; Department of Oncology, GZA Ziekenhuizen Campus Sint-Augustinus, 2610, Antwerp, Belgium.
  • Ferrero JM; Department of Oncology, Centre Antoine Lacassagne, 06189, Nice, France.
  • Bonnefoi H; Medical Oncology Department, Institut Bergonié, 33000, Bordeaux, France.
  • Canon JL; Department of Oncology-Hematology, Grand Hôpital de Charleroi - Site Notre Dame, 6000, Charleroi, Belgium.
  • Duhoux FP; Medical Oncology Department, Cliniques Universitaires Saint-Luc (UCLouvain), 1200, Brussels, Belgium.
  • Mansi L; Department of Oncology, CHU Besançon - Hôpital Jean Minjoz, 25030, Besancon, France.
  • Poncin R; Medical Oncology Department, Clinique Saint-Pierre, 1340, Ottignies-Louvain-la-Neuve, Belgium.
  • Barthélémy P; Medical Oncology Department, Institut de Cancérologie Strasbourg Europe (ICANS), 67000, Strasbourg, France.
  • Isambert N; Medical Oncology Department, CHU Poitiers, 86000, Poitiers, France.
  • Denis Z; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Catteau X; CurePath Laboratory (CHU Tivoli, CHIREC), 6040, Jumet, Belgium.
  • Salgado R; Department of Pathology, GZA-ZNA Hospitals, 2610, Antwerp, Belgium.
  • Agostinetto E; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • de Azambuja E; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Rothé F; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Craciun L; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Venet D; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Romano E; Centre for Cancer Immunotherapy, Medical Oncology Department, INSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.
  • Stagg J; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, QC, 11290, Canada.
  • Paesmans M; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Larsimont D; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Sotiriou C; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Ignatiadis M; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
  • Piccart-Gebhart M; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
Nat Commun ; 14(1): 8223, 2023 Dec 12.
Article in En | MEDLINE | ID: mdl-38086864
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2023 Type: Article Affiliation country: Belgium
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2023 Type: Article Affiliation country: Belgium